Immix Biopharma notes termination of employee

Q: What event did Immix Biopharma (IMMX) report in this 8-K?

Immix Biopharma reported that Richard Graydon’s employment was terminated as of July 17, 2026. The company stated his departure is unrelated to his activities there and management believes it has no material effect on the business.

Q: When did Richard Graydon leave Immix Biopharma (IMMX)?

Richard Graydon’s employment with Immix Biopharma ended as of July 17, 2026. This date marks the effective termination, and the company indicated that his short tenure limits any business impact.

Q: Did Immix Biopharma (IMMX) link Richard Graydon’s termination to misconduct?

No. Immix Biopharma stated that Richard Graydon was terminated for reasons unrelated to his activities at the company. The disclosure does not allege misconduct and emphasizes no material business effect.

Q: How material is Richard Graydon’s departure to Immix Biopharma (IMMX)?

Management believes Richard Graydon’s departure has no material effect on the business. They attribute this assessment to his short tenure at the company, suggesting limited operational impact.

Immix Biopharma, Inc. reported that as of July 17, 2026, Richard Graydon has been terminated and is no longer with the company.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Immix Biopharma, Inc. reported that as of July 17, 2026, Richard Graydon has been terminated and is no longer with the company. The company states that the departure is for reasons unrelated to his activities at Immix Biopharma.

Given his short tenure, management believes this change has no material effect on the business.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Terms

Emerging growth company, Exchange Act, pre-commencement communications

3 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Exchange Act regulatory

"under the Exchange Act (17 CFR 240.14d-2(b)"

A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.

pre-commencement communications regulatory

"Pre-commencement communications pursuant to Rule 14d-2(b)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event did Immix Biopharma (IMMX) report in this 8-K?

Immix Biopharma reported that Richard Graydon’s employment was terminated as of July 17, 2026. The company stated his departure is unrelated to his activities there and management believes it has no material effect on the business.

When did Richard Graydon leave Immix Biopharma (IMMX)?

Richard Graydon’s employment with Immix Biopharma ended as of July 17, 2026. This date marks the effective termination, and the company indicated that his short tenure limits any business impact.

Did Immix Biopharma (IMMX) link Richard Graydon’s termination to misconduct?

No. Immix Biopharma stated that Richard Graydon was terminated for reasons unrelated to his activities at the company. The disclosure does not allege misconduct and emphasizes no material business effect.

How material is Richard Graydon’s departure to Immix Biopharma (IMMX)?

Management believes Richard Graydon’s departure has no material effect on the business. They attribute this assessment to his short tenure at the company, suggesting limited operational impact.

Who signed the Immix Biopharma (IMMX) report about Richard Graydon’s termination?

The report regarding Richard Graydon’s termination was signed by Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. His signature reflects the company’s formal acknowledgment of the personnel change.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/20/2026 - 06:05 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 20, 2026

IMMIX BIOPHARMA, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-41159

45-4869378

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

11400 West Olympic Blvd., Suite 200

Los Angeles, CA 90064

(Address of principal executive offices)

(310) 651-8041

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b)of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value of $0.0001 per share		IMMX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As of July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the Company. Given his short tenure, management believes there is no material effect on the business.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Immix Biopharma, Inc.

Dated: July 20, 2026	/s/ Ilya Rachman
	Ilya Rachman, M.D., Ph.D.
	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents